VICP Vicapsys Life Sciences, Inc.

CIK 0001468639 8 ready 8-Ks latest December 27, 2023, 6:59 PM ET RSS · JSON

Ready 8-Ks 8

Latest filing December 27, 2023, 6:59 PM ET

Top materiality 0.75

Event mix other_material ×3 · leadership ×3 · debt ×2

Sentiment 1 pos · 1 neg · 6 neu

Executive change recent →

Recent 8-K filings for VICP

Highest-materiality recent filing

Vicapsys Life Sciences issues $330K note to AJB Capital, 10% interest, 8% OID, due Dec 2023

June 30, 2023, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Debt Financings◈ Material Agreements

Principal $330,000, purchase price $303,600 (8% OID), 10% annual interest, maturity December 27, 2023.
Issued 328,571 unregistered commitment fee shares to AJB Capital as part of the agreement.

Read filing →

December 27, 2023, 6:59 PM ET debt materiality 0.30 neutral item 1.01 item 2.03 item 9.01 ◈ Debt Financings

Vicapsys Life Sciences modifies promissory note with AJB Capital, extends maturity and increases principal to $363K

Extended maturity date of $330K promissory note to January 27, 2024.
June 30, 2023, 7:59 PM ET debt materiality 0.75 neutral item 1.01 item 2.03 item 3.02 item 9.01 ◈ Debt Financings◈ Material Agreements

Vicapsys Life Sciences issues $330K note to AJB Capital, 10% interest, 8% OID, due Dec 2023

Principal $330,000, purchase price $303,600 (8% OID), 10% annual interest, maturity December 27, 2023.
June 2, 2023, 7:59 PM ET other material materiality 0.25 neutral item 1.01 item 9.01 ◈ Material Agreements

Vicapsys Life Sciences amends patent license with Massachusetts General Hospital, adding new patent rights

Ninth Amendment adds Patent Rights MGH 24644 (PCT/US2018/051950) to exclusive license.
May 18, 2023, 7:59 PM ET other material materiality 0.30 neutral item 4.01 item 9.01 ◈ Auditor Changes ×2

Vicapsys Life Sciences amends 8-K to correct new auditor name to Assurance Dimensions

Dismissed D. Brooks and Associates CPAs as auditor effective May 12, 2023; their reports included a going-concern doubt.
May 17, 2023, 7:59 PM ET other material materiality 0.60 negative item 4.01 item 9.01 ◈ Auditor Changes ×2

Vicapsys Life Sciences dismisses auditor D. Brooks and appoints Assurance Dimensions

Board dismissed D. Brooks and Associates CPAs as independent auditor effective May 12, 2023.
January 12, 2023, 6:59 PM ET leadership materiality 0.50 neutral item 5.02 item 9.01

Vicapsys Life Sciences enters CEO employment agreement with $250k base salary, performance-based equity

CEO Federico Pier receives $250k annual base salary, subject to annual increase by Board.
September 28, 2022, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change ×5

Vicapsys Life Sciences: Potts and Yurkowsky resign; Farrahar, Delaney, Rosenblum join board

Board accepted resignations of directors John Potts and Michael Yurkowsky effective September 22, 2022; no disagreement.
April 12, 2022, 7:59 PM ET leadership materiality 0.60 positive item 5.02 item 8.01 item 9.01 ◈ executive_change

Vicapsys Life Sciences appoints Federico Pier as CEO, effective Feb 15, 2022

Federico Pier appointed CEO effective Feb 15, 2022; previously interim CEO since Aug 2020 and Executive Chairman since May 2019.